PP_1170x120_10-25-21

type 2 diabetes medication

Novo Nordisk set to release Ozempic

Novo Nordisk set to release Ozempic

PLAINSBORO, N.J. — Novo Nordisk this week gained Food and Drug Administration approval for Ozempic (semaglutide injection), a medication for type 2 diabetes. Also this week, Novo Nordisk and pharmacy benefit manager Prime Therapeutics said they signed a value-based contract for Victoza (liraglutide injection), another type 2 diabetes medication. A glucagon-like peptide (GLP-1) receptor agonist,

Janssen cleared to market Invokamet XR

Janssen cleared to market Invokamet XR

RARITAN, N.J. — Janssen Pharmaceuticals Inc. has received approval from the Food and Drug Administration for Invokamet XR, a type 2 diabetes medication. The Johnson & Johnson subsidiary said Invokamet XR, a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release, is indicated for first-line use as an adjunct to diet and exercise to